- Conditions
- Cancer
- Interventions
- GSK2110183 (afuresertib)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 8,146
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Low-grade Oral Dysplasia
- Interventions
- Probiotic oral lozenges, Standard of care for oral dysplasia
- Biological · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteer
- Interventions
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
- Procedure · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Minneapolis, Minnesota
- Conditions
- Dementia, Delirium
- Interventions
- Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 11
- States / cities
- Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
- Conditions
- Periodontal Disease
- Interventions
- Periodontal therapy
- Other
- Lead sponsor
- The Forsyth Institute
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 5
- States / cities
- Edwardsville, Illinois • Cambridge, Massachusetts • Ann Arbor, Michigan + 2 more
- Conditions
- Asthma
- Interventions
- Roflumilast
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 819 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 37
- States / cities
- Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 34 more
- Conditions
- Invasive Aspergillosis
- Interventions
- Posaconazole IV, Posaconazole PFS, Posaconazole tablet
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Orange, California • San Diego, California • Chicago, Illinois + 1 more
- Conditions
- Recurrent Small Cell Lung Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Topotecan Hydrochloride
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Iron Deficiency Anemia
- Interventions
- Sodium Ferric Gluconate Complex, Oral Iron
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease, Healthy
- Interventions
- GSI-136, Placebo
- Drug · Other
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Bethesda, Maryland • Oklahoma City, Oklahoma
- Conditions
- Head and Neck Cancer
- Interventions
- Optical Spectroscopy
- Device
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
- Interventions
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Drug
- Lead sponsor
- Tactical Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 4
- States / cities
- New York, New York • Portland, Oregon
- Conditions
- Chronic Osteoarthritis Pain, Chronic Low Back Pain
- Interventions
- PIPE-791, Placebo
- Drug
- Lead sponsor
- Contineum Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
- Conditions
- Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
- Interventions
- Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metahdone-maintenance Subjects
- Interventions
- MOA-728
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Active Comparator CT1812, Placebo Comparator
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more
- Conditions
- Asthma
- Interventions
- Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 12
- States / cities
- Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
- Conditions
- Emergency Contraception
- Interventions
- Copper IUD, Levonorgestrel IUD
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Periodontal Diseases
- Interventions
- Microsurgical approach with Digital Microscope
- Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Norovirus Infections
- Interventions
- VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas